Loading clinical trials...
Loading clinical trials...
A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)
Conditions
Interventions
Once weekly subcutaneous injection of TransCon hGH
Once daily subcutaneous injection of Genotropin
Locations
53
United States
Ascendis Pharma Investigational Site
Birmingham, Alabama, United States
Ascendis Pharma Investigational Site
Little Rock, Arkansas, United States
Ascendis Pharma Investigational Site
Los Angeles, California, United States
Ascendis Pharma Investigational Site
Orange, California, United States
Ascendis Pharma Investigational Site
Centennial, Colorado, United States
Ascendis Pharma Investigational Site
Jacksonville, Florida, United States
Start Date
December 13, 2016
Primary Completion Date
January 17, 2019
Completion Date
January 17, 2019
Last Updated
January 4, 2022
NCT06112340
NCT02710370
NCT06619834
NCT05749770
NCT05022667
NCT04809220
Lead Sponsor
Ascendis Pharma Endocrinology Division A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions